MedTrace Logo

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

NCT01118598 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2019-07-15

No results posted yet for this study

Summary

Niacin will improve postprandial hyperlipidaemia and cardiovascular risks indices via its lipid lowering as well as via pleiotropic effects in patients with polycystic ovary syndrome (PCOS).

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

tredaptive (nicotinic acid/ laropiprant)

tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks

DRUG

placebo

placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Stephen L Atkin, FRCP, PhD · University of Hull

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118598 on ClinicalTrials.gov